New Antibody-conjugated Drugs Promise to Improve Bone Marrow Transplantation

1
New Antibody-conjugated Drugs Promise to Improve
Bone Marrow Transplantation
www.creative-biolabs.com/adc
2
Background
Recently, Magenta Therapeutic, a cutting-edge
company based in Cambridge, United States,
announced that it has reached a patent license
agreement with German biotechnology company
Heidelberg Pharma to jointly develop
antibody-conjugated drugs (ADCs) for improving
pretreatment before bone marrow transplantation.
3
Bone marrow transplantation
Bone marrow transplantation is hematopoietic stem
cell transplantation. It is a treatment method
for the treatment of a series of diseases by
intravenous infusion of hematopoietic stem and
progenitor cells to reconstruct the patient's
normal hematopoietic and immune systems.
Hematopoietic stem cell transplantation basically
replaces the term bone marrow transplantation
because hematopoietic stem cells are not only
derived from bone marrow but also from peripheral
blood that can be mobilized by hematopoietic
factors. They can also be derived from cord blood
to rebuild blood and immune system.
4
Magenta focused on improving stem cell
transplantation. Its stem cell transplantation
project has raised 98.5 million in funds. It has
been favored by famous investors such as Google
and established an authorized cooperation
relationship with Novartis. At the same time, it
attracted former Pfizer executives and drug
development experts. Dr. John Davis joined the
chief medical officer.
5
The challenge of transplantation
Pretreatment before stem cell transplantation is
a big challenge. In order to reduce transplant
rejection, patients must undergo pretreatment
prior to receiving the transplant. The stem cells
and diseased cells in the patient's bone marrow
must be removed in advance to prevent
transplanted stem cells from being rejected after
entering the body. This process usually requires
high-toxicity, high-dose radiotherapy, and there
is a greater risk of toxicity and infection.
Magenta scientists have discovered a variety of
ADC drug, including antibody components that can
specifically recognize stem cells and diseased
cells, and target delivery of conjugated drugs to
stem cells and diseased cells to specifically
eliminate stem cells and pathologies. cell.
6
Conclusion
Targeted pretreatment programs are a significant
medical requirement in the bone marrow
transplantation field. This is where Magenta
focuses its attention, said Dr. Michael Cooke,
Magenta's chief scientific officer. In the
treatment project, we explored the discovery that
Amanitin is a promising conjugated payload. Our
cooperation with Heidelberg will allow us to
fully evaluate the potential value of this class
of antibody-conjugated drugs.
7
As a global company, we have more than 200
talented and well-trained scientists located in
different continents working closely with
partners from the entire world to develop and
produce medicines of tomorrow. Specifically, we
are the established leading expert in TCR and CAR
TNK cell immune therapy development, as we offer
the one-stop custom services that cover the
entire new drug development pipeline.
Creative Biolabs
8
As a global company, we have more than 200
talented and well-trained scientists located in
different continents working closely with
partners from the entire world to develop and
produce medicines of tomorrow. Specifically, we
are the established leading expert in TCR and CAR
TNK cell immune therapy development, as we offer
the one-stop custom services that cover the
entire new drug development pipeline.
Creative Biolabs
9
Contact Us
45-1 Ramsey Road, Shirley, NY 11967, USA
Email marketing_at_creative-biolabs.com
10
Thank you